Background
Case presentation
WBC | 13,200/μL | CK | 36 IU/L |
Neu | 92.4% | γ-GTP | 129 IU/L |
Lym | 5.3% | Amy | 61 IU/L |
Mono | 1.9% | TP | 7.3 g/dL |
Eos | 0.1% | Alb | 4.2 g/dL |
RBC | 410 × 104/μL | BUN | 9.6 mg/dL |
Hb | 11.7 g/dL | Cre | 0.6 mg/dL |
Plt | 19.2 × 104/μL | Na | 136 mmol/L |
AST | 30 IU/L | K | 4.1 mmol/L |
ALT | 63 IU/L | Cl | 98 mmol/L |
T-Bil | 1.1 mg/dL | Ca | 9.1 mg/dL |
LDH | 180 IU/L | Glu | 66 mg/dL |
ALP | 341 IU/L | CRP | 17.7 mg/dL |
Antimicrobial agents | MIC (μg/mL) | Interpretation |
---|---|---|
Ampicillin | ≤ 8 | S |
Minocycline | ≤ 4 | S |
Amikacin | ≤ 4 | S |
Aztreonam | ≤ 1 | S |
Ceftazidime | ≤ 1 | S |
Cefazolin | 8 | R |
Cefepime | ≤ 2 | S |
Cefmetazole | ≤ 16 | S |
Ciprofloxacin | ≤ 0.063 | S |
Cefotiam | ≤ 2 | |
Cefotaxime | ≤ 1 | S |
Fosfomycin | ≤ 64 | |
Imipenem | ≤ 0.5 | S |
Levofloxacin | ≤ 0.125 | S |
Piperacillin | ≤ 16 | S |
Trimethoprim/sulfamethoxazole | ≤ 2/38 | S |
Meropenem | ≤ 0.125 | S |
Tazobactam/piperacillin | ≤ 4/4 | S |
Discussion
Author (year) | Sex | Age | Site of infection | Underlying disease | Treatment | Outcome |
---|---|---|---|---|---|---|
Schmid et al. (2003) [4] | F | 71 | Respiratory infection | Acute myeloid leukemia | CAM AMPC/CVA | Improved |
Hagiya and Otsuka (2014) [6] | M | 64 | Bloodstream infection Bacteremia | DCM DM SSS | Cefepime | Improved |
Mehar et al. (2013) [5] | ND | Neonate | Sepsis | Not described | TAZ/PIPC AMK | Improved |
Mehar et al. (2013) [5] | ND | Neonate | Sepsis | Not described | SBT/ABPC AMK | Improved |
Current case | F | 38 | Bacteremia Cholangitis | Choledocholithiasis | Meropenem | Improved |